These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. Castellvi J; Garcia A; de la Torre J; Hernandez J; Gil A; Xercavins J; Ramón y Cajal S Hum Pathol; 2006 Jul; 37(7):883-9. PubMed ID: 16784989 [TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Sakata K; Shigemasa K; Nagai N; Ohama K Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877 [TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
5. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors. Li M; Qi SY; Wang Y; Feng SX; Zhang BZ; Wang R Arch Gynecol Obstet; 2005 Jun; 272(1):48-52. PubMed ID: 15682318 [TBL] [Abstract][Full Text] [Related]
6. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113 [TBL] [Abstract][Full Text] [Related]
7. Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M Anticancer Res; 2002; 22(6A):3191-6. PubMed ID: 12530064 [TBL] [Abstract][Full Text] [Related]
8. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246 [TBL] [Abstract][Full Text] [Related]
9. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106 [TBL] [Abstract][Full Text] [Related]
10. Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67. Kohlberger PD; Kieback DG; Mian C; Wiener H; Kainz C; Gitsch G; Breitenecker G J Soc Gynecol Investig; 1997; 4(5):262-4. PubMed ID: 9360232 [TBL] [Abstract][Full Text] [Related]
11. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444 [TBL] [Abstract][Full Text] [Related]
12. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549 [TBL] [Abstract][Full Text] [Related]
14. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721 [TBL] [Abstract][Full Text] [Related]
15. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tai Y; Tokuda M Clin Cancer Res; 2001 Dec; 7(12):4130-5. PubMed ID: 11751512 [TBL] [Abstract][Full Text] [Related]
16. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Arts HJ; de Jong S; Hollema H; Ten Hoor KA; de Vries EG; van der Zee AG Int J Oncol; 2005 Feb; 26(2):379-84. PubMed ID: 15645122 [TBL] [Abstract][Full Text] [Related]
17. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis B; Agnantis NJ Anticancer Res; 2004; 24(3a):1665-70. PubMed ID: 15274338 [TBL] [Abstract][Full Text] [Related]
18. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. De Sousa Damião R; Fujiyama Oshima CT; Stávale JN; Gonçalves WJ Oncol Rep; 2007 Jul; 18(1):25-32. PubMed ID: 17549341 [TBL] [Abstract][Full Text] [Related]
19. Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Sui L; Dong Y; Watanabe Y; Yamaguchi F; Sugimoto K; Tokuda M Oncol Rep; 2006 Apr; 15(4):773-8. PubMed ID: 16525657 [TBL] [Abstract][Full Text] [Related]
20. [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. Qiao YH; Cheng J; Guo RX Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):325-9. PubMed ID: 17673045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]